Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3954068 intrathecal single and multiple ascending dose study in early symptomatic Alzheimer's disease
jRCT2051240006Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of LY3954068 in Alzheimer's disease (AD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Part A safety and tolerability and Part B safety and tolerability. Started Aug 2024; status: recruiting.
02
Drugs
LY3954068
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2051240006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240006.